{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:45:00Z","timestamp":1785275100305,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Seoul National University College of Medicine Research Fund","award":["2018"],"award-info":[{"award-number":["2018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-018-5211-y","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T13:25:14Z","timestamp":1546694714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin"],"prefix":"10.1186","volume":"19","author":[{"given":"Min su","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-0491","authenticated-orcid":false,"given":"Ji Kon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunn","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Hyun","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"issue":"5","key":"5211_CR1","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/jso.24546","volume":"115","author":"C Are","year":"2017","unstructured":"Are C, Ahmad H, Ravipati A, Croo D, Clarey D, Smith L, Price RR, Butte JM, Gupta S, Chaturvedi A, et al. Global epidemiological trends and variations in the burden of gallbladder cancer. J Surg Oncol. 2017;115(5):580\u201390.","journal-title":"J Surg Oncol"},{"issue":"6","key":"5211_CR2","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1572-0241.2000.02070.x","volume":"95","author":"S Sheth","year":"2000","unstructured":"Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95(6):1402\u201310.","journal-title":"Am J Gastroenterol"},{"key":"5211_CR3","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109.","journal-title":"Clin Epidemiol"},{"issue":"14","key":"5211_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"5211_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00280-017-3341-6","volume":"80","author":"Y Hirooka","year":"2017","unstructured":"Hirooka Y, Ishikawa T, Kawashima H, Ohno E, Nonogaki K, Kanamori A, Hirai T, Uchida H, Shirai O, Ishikawa H, et al. Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer. Cancer Chemother Pharmacol. 2017;80(1):119\u201325.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"5211_CR6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.7314\/APJCP.2012.13.4.1317","volume":"13","author":"K Qu","year":"2012","unstructured":"Qu K, Liu S-N, Chang H-L, Liu C, Xu X-S, Wang R-T, Zhou L, Tian F, Wei J-C, Tai M-H, et al. Gallbladder Cancer: a subtype of biliary tract Cancer which is a current challenge in China. Asian Pac J Cancer Prev. 2012;13(4):1317\u201320.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"11","key":"5211_CR7","doi-asserted-by":"publisher","first-page":"e0166361","DOI":"10.1371\/journal.pone.0166361","volume":"11","author":"C Chen","year":"2016","unstructured":"Chen C, Geng Z, Shen H, Song H, Zhao Y, Zhang G, Li W, Ma L, Wang L. Long-term outcomes and prognostic factors in advanced gallbladder Cancer: focus on the advanced T stage. PLoS One. 2016;11(11):e0166361.","journal-title":"PLoS One"},{"issue":"9","key":"5211_CR8","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1245\/s10434-016-5243-y","volume":"23","author":"N Amini","year":"2016","unstructured":"Amini N, Kim Y, Wilson A, Margonis GA, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, et al. Prognostic implications of lymph node status for patients with gallbladder Cancer: a multi-institutional study. Ann Surg Oncol. 2016;23(9):3016\u201323.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"5211_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/bjs.10401","volume":"104","author":"Y Yamamoto","year":"2017","unstructured":"Yamamoto Y, Sugiura T, Ashida R, Okamura Y, Ito T, Uesaka K. Indications for major hepatectomy and combined procedures for advanced gallbladder cancer. Br J Surg. 2017;104(3):257\u201366.","journal-title":"Br J Surg"},{"key":"5211_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1186\/1471-2407-14-652","volume":"14","author":"XW Yang","year":"2014","unstructured":"Yang XW, Yuan JM, Chen JY, Yang J, Gao QG, Yan XZ, Zhang BH, Feng S, Wu MC. The prognostic importance of jaundice in surgical resection with curative intent for gallbladder cancer. BMC Cancer. 2014;14:652.","journal-title":"BMC Cancer"},{"issue":"2","key":"5211_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.amjsurg.2007.11.011","volume":"196","author":"S Gourgiotis","year":"2008","unstructured":"Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg. 2008;196(2):252\u201364.","journal-title":"Am J Surg"},{"issue":"12","key":"5211_CR12","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3760\/cma.j.issn.0366-6999.20131734","volume":"127","author":"T Yu","year":"2014","unstructured":"Yu T, Yu H, Cai X. Preoperative prediction of survival in resectable gallbladder cancer by a combined utilization of CA 19-9 and carcinoembryonic antigen. Chin Med J. 2014;127(12):2299\u2013303.","journal-title":"Chin Med J"},{"issue":"14","key":"5211_CR13","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.3748\/wjg.v20.i14.4085","volume":"20","author":"YF Wang","year":"2014","unstructured":"Wang YF, Feng FL, Zhao XH, Ye ZX, Zeng HP, Li Z, Jiang XQ, Peng ZH. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 2014;20(14):4085\u201392.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"5211_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.hpb.2016.03.608","volume":"18","author":"L Zhang","year":"2016","unstructured":"Zhang L, Wang R, Chen W, Xu X, Dong S, Fan H, Liu C. Prognostic significance of neutrophil to lymphocyte ratio in patients with gallbladder carcinoma. HPB (Oxford). 2016;18(7):600\u20137.","journal-title":"HPB (Oxford)"},{"issue":"13","key":"5211_CR15","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1097\/MD.0000000000000574","volume":"94","author":"Q Chen","year":"2015","unstructured":"Chen Q, Dai Z, Yin D, Yang LX, Wang Z, Xiao YS, Fan J, Zhou J. Negative impact of preoperative platelet-lymphocyte ratio on outcome after hepatic resection for intrahepatic cholangiocarcinoma. Medicine (Baltimore). 2015;94(13):e574.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"5211_CR16","first-page":"3229","volume":"37","author":"Y Kitano","year":"2017","unstructured":"Kitano Y, Yamashita YI, Yamamura K, Arima K, Kaida T, Miyata T, Nakagawa S, Mima K, Imai K, Hashimoto D, et al. Effects of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios on survival in patients with extrahepatic cholangiocarcinoma. Anticancer Res. 2017;37(6):3229\u201337.","journal-title":"Anticancer Res"},{"key":"5211_CR17","volume-title":"AJCC Cancer staging manual","year":"2017","unstructured":"Amin M, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer staging manual. New York: 8th Springer; 2017."},{"issue":"2","key":"5211_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"5211_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","volume":"30","author":"C Contal","year":"1999","unstructured":"Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 1999;30(3):253\u201370.","journal-title":"Comput Stat Data Anal"},{"issue":"3","key":"5211_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s002689900380","volume":"22","author":"Y Ogura","year":"1998","unstructured":"Ogura Y, Tabata M, Kawarada Y, Mizumoto R. Effect of hepatic invasion on the choice of hepatic resection for advanced carcinoma of the gallbladder: histologic analysis of 32 surgical cases. World J Surg. 1998;22(3):262\u20136 discussion 266-267.","journal-title":"World J Surg"},{"issue":"5","key":"5211_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3748\/wjg.v11.i5.748","volume":"11","author":"H-T Lin","year":"2005","unstructured":"Lin H-T, Liu G-J, Wu D, Lou J-Y. Metastasis of primary gallbladder carcinoma in lymph node and liver. World J Gastroenterol. 2005;11(5):748\u201351.","journal-title":"World J Gastroenterol"},{"key":"5211_CR22","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers (v.3.2018). 2018, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf . Accessed 2 Oct 2018."},{"issue":"4","key":"5211_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.4143\/crt.2016.538","volume":"49","author":"HS Park","year":"2017","unstructured":"Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, Choi HJ, Park JS, Lee DK, Lee SJ, et al. Prognostic factors and scoring model for survival in metastatic biliary tract Cancer. Cancer Res Treat. 2017;49(4):1127\u201339.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"5211_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4143\/crt.2016.326","volume":"49","author":"DW Lee","year":"2017","unstructured":"Lee DW, Im SA, Kim YJ, Yang Y, Rhee J, Na II, Lee KH, Kim TY, Han SW, Choi IS, et al. CA19-9 or CEA decline after the first cycle of treatment predicts survival in advanced biliary tract Cancer patients treated with S-1 and cisplatin chemotherapy. Cancer Res Treat. 2017;49(3):807\u201315.","journal-title":"Cancer Res Treat"},{"issue":"9","key":"5211_CR25","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","volume":"50","author":"MG McNamara","year":"2014","unstructured":"McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Amir E, Knox JJ. Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50(9):1581\u20139.","journal-title":"Eur J Cancer"},{"issue":"4","key":"5211_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1023\/B:AGEN.0000029415.62384.ba","volume":"6","author":"YH Kusumanto","year":"2003","unstructured":"Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283\u20137.","journal-title":"Angiogenesis"},{"issue":"9255","key":"5211_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539\u201345.","journal-title":"Lancet"},{"issue":"7203","key":"5211_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436\u201344.","journal-title":"Nature"},{"issue":"2","key":"5211_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.21037\/jgo.2016.09.16","volume":"8","author":"S Sahu","year":"2017","unstructured":"Sahu S, Sun W. Targeted therapy in biliary tract cancers\u2014current limitations and potentials in the future. J Gastrointest Oncol. 2017;8(2):324\u201336.","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"5211_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.clinimag.2012.05.009","volume":"37","author":"B Li","year":"2013","unstructured":"Li B, Xu XX, Du Y, Yang HF, Li Y, Zhang Q, Xiao DM, Huang YY, Meng J, Wang WX. Computed tomography for assessing resectability of gallbladder carcinoma: a systematic review and meta-analysis. Clin Imaging. 2013;37(2):327\u201333.","journal-title":"Clin Imaging"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5211-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T20:53:41Z","timestamp":1720904021000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5211"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5211-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"21 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Institutional Review Board of the Seoul National University Hospital, Seoul, Korea (1703\u2013004-834). Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"10"}}